Abstract
Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, controls the expression of genes encoding cytoprotective proteins, including antioxidant enzymes that combat oxidative and electrophilic stress to maintain redox homeostasis. However, recent studies demonstrated that, in cancer, aberrant activation of Nrf2 by epigenetic alterations promotes high expression of cytoprotective proteins, which can decrease the efficacy of anticancer drugs used for chemotherapy. In this review, we summarize recent findings regarding the relationship between oxidative stress, Nrf2, epigenetic modification, and anticancer drug resistance, which should aid in development of new strategies to improve chemotherapeutic efficacy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Reference
Bai, X., Chen, Y., Hou, X., Huang, M. and Jin, J. (2016) Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters. Drug Metab. Rev., 48, 541–567.
Furfaro, A.L., Piras, S., Domenicotti, C., Fenoglio, D., De Luigi, A., Salmona, M., Moretta, L., Marinari, U.M., Pronzato, M.A., Traverso, N. and Nitti, M. (2016) Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib. PLoS ONE, 11, e0152465.
Guo, Y., Yu, S., Zhang, C. and Kong, A.N. (2015) Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med., 88, 337–349.
Seton-Rogers, S. (2016) Chemotherapy: preventing competitive release. Nat. Rev. Cancer, 16, 199.
Holohan, C., Van Schaeybroeck, S., Longley, D.B. and Johnston, P.G. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer, 13, 714–726.
Ramos, P. and Bentires-Alj, M. (2015) Mechanism-based cancer therapy: resistanceto therapy, therapy for resistance. Oncogene, 34, 3617–3626.
Gorrini, C., Harris, I.S. and Mak, T.W. (2013) Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov., 12, 931–947.
Trachootham, D., Alexandre, J. and Huang, P. (2009) Targeting cancercells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov., 8, 579–591.
Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E.C., Zhang, H., Huang, C. and Lei, Y. (2016) Cancer drug resistance: redox resetting renders a way. Oncotarget, 7, 42740–42761.
Debatin, K.M. and Krammer, P.H. (2004) Death receptors in chemotherapy and cancer. Oncogene, 23, 2950–2966.
Ren, D., Villeneuve, N.F., Jiang, T., Wu, T., Lau, A., Toppin, H.A. and Zhang, D.D. (2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U.S.A., 108, 1433–1438.
DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., Scrimieri, F., Winter, J.M., Hruban, R.H., Iacobuzio-Donahue, C., Kern, S.E., Blair, I.A. and Tuveson, D.A. (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106–109.
Zhang, Y. and Gordon, G.B. (2004) A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol. Cancer Ther., 3, 885–893.
Giudice, A., Arra, C. and Turco, M.C. (2010) Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol. Biol., 647, 37–74.
Chio, I.I., Jafarnejad, S.M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., Wright, K., Filippini, D., Lee, E.J., Da Silva, B., Schoepfer, C., Wilkinson, J.E., Buscaglia, J.M., DeNicola, G.M., Tiriac, H., Hammell, M., Crawford, H.C., Schmidt, E.E., Thompson, C.B., Pappin, D.J., Sonenberg, N. and Tuveson, D.A. (2016) NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell, 166, 963–976.
Sporn, M.B. and Liby, K.T. (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer, 12, 564–571.
Na, H.K. and Surh, Y.J. (2014) Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic. Biol. Med., 67, 353–365.
Shen, L., Song, C.X., He, C. and Zhang, Y. (2014) Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu. Rev. Biochem., 83, 585–614.
Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C. and Zhang, Y. (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science, 333, 1300–1303.
Shilatifard, A. (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin. Cell Biol., 20, 341–348.
Coward, W.R., Feghali-Bostwick, C.A., Jenkins, G., Knox, A.J. and Pang, L. (2014) A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. FASEB J., 28, 3183–3196.
Yang, D., Okamura, H., Teramachi, J. and Haneji, T. (2016) Histone demethylase Jmjd3 regulates osteoblast apoptosis through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim. Biochim. Biophys. Acta, 1863, 650–659.
Wang, R., An, J., Ji, F., Jiao, H., Sun, H. and Zhou, D. (2008) Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem. Biophys. Res. Commun., 373, 151–154.
Muscarella, L.A., Barbano, R., D’Angelo, V., Copetti, M., Coco, M., Balsamo, T., la Torre, A., Notarangelo, A., Troiano, M., Parisi, S., Icolaro, N., Catapano, D., Valori, V. M., Pellegrini, F., Merla, G., Carella, M., Fazio, V.M. and Parrella, P. (2011) Regulation of Keap1 expression by promoter methylation in malignant gliomas and association with patient’s outcome. Epigenetics, 6, 317–325.
Li, Z., Xu, L., Tang, N., Xu, Y., Ye, X., Shen, S., Niu, X., Lu, S. and Chen, Z. (2014) The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett., 588, 3000–3007.
Kang, K.A., Piao, M.J., Kim, K.C., Kang, H.K., Chang, W.Y., Park, I.C., Keum, Y.S., Surh, Y.J. and Hyun, J.W. (2014) Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis., 5, e1183.
Kang, K.A., Piao, M.J., Ryu, Y.S., Kang, H.K., Chang, W.Y., Keum, Y.S. and Hyun, J.W. (2016) Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells. Oncotarget, 7, 40594–40620.
Mohan, M., Herz, H.M., Smith, E.R., Zhang, Y., Jackson, J., Washburn, M.P., Florens, L., Eissenberg, J.C. and Shilatifard, A. (2011) The COMPASS family of H3K4 methylases in Drosophila. Mol. Cell. Biol., 31, 4310–4318.
Deplus, R., Delatte, B., Schwinn, M.K., Defrance, M., Méndez, J., Murphy, N., Dawson, M.A., Volkmar, M., Putmans, P., Calonne, E., Shih, A.H., Levine, R.L., Bernard, O., Mercher, T., Solary, E., Urh, M., Daniels, D.L. and Fuks, F. (2013) TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J., 32, 645–655.
Ardehali, M.B., Mei, A., Zobeck, K.L., Caron, M., Lis, J.T. and Kusch, T. (2011) Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription. EMBO J., 30, 2817–2828.
Capotosti, F., Guernier, S., Lammers, F., Waridel, P., Cai, Y., Jin, J., Conaway, J.W., Conaway, R.C. and Herr, W. (2011) O-GlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell, 144, 376–388.
Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kitabayashi, I., Herr, W. and Cleary, M.L. (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol., 24, 5639–5649.
Ding, X., Jiang, W., Zhou, P., Liu, L., Wan, X., Yuan, X., Wang, X., Chen, M., Chen, J., Yang, J., Kong, C., Li, B., Peng, C., Wong, C.C., Hou, F. and Zhang, Y. (2015) Mixed lineage leukemia 5 (MLL5) protein stability is cooperatively regulated by O-GlcNac transferase (OGT) and ubiquitin specific protease 7 (USP7). PLoS ONE, 10, e0145023.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://doi.org/creativecommons.org/licenses/by/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kang, K.A., Hyun, J.W. Oxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance. Toxicol Res. 33, 1–5 (2017). https://doi.org/10.5487/TR.2017.33.1.001
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2017.33.1.001